Floatz logo

mk-4830

High-grade Serous Ovarian Carcinoma

Merck Sharp & Dohme LLCPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

114 Active assets in the High-grade Serous Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
Olaparib
Institute of Cancer Research, United Kingdom
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 2/3BB
Letrozole
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

mk-4830 is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
ovarian carcinomaDormant
B
Indicative ·
57 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →